首页|P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [vol 21, Pg S152, 2021)

P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [vol 21, Pg S152, 2021)

扫码查看
原文链接
  • NSTL
  • Cig Media Group, Lp

Moreau, Philippe、Parmar, Gurdeep、Prince, Miles、Ocio, Enrique M.、Karanes, Chatchada、Madan, Sumit、Oriol, Albert、Bories, Pierre、Delforge, Michel、Gabrail, Nashat、Jia, Nan、Macc, Sandrine、Suzan, Florence、van de Velde, Helgi、Quach, Hang、Semiond, Dorothee

展开 >

Univ Hosp Nantes

Illawarra Canc Care Ctr

Epworth Healthcare

Univ Cantabria

City Hope Natl Med Ctr

Banner MD Anderson Canc Ctr

Inst Catala Oncol,Hosp Badalona Germans Trias & Pujol

Reseau Reg Cancerol Oncoccitanie

Univ Hosp Leuven

Gabrail Canc Ctr

Sanofi

St Vincents Hosp,Univ Melbourne

展开 >

2022

10.1016/j.clml.2022.03.009

Clinical lymphoma, myeloma & leukemia

Clinical lymphoma, myeloma & leukemia

ISSN：2152-2650
年,卷(期)：2022.22(6)
  • 1